<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Trachoma</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Trachoma</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Trachoma</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Anna Last, BMedSc, MBChB, MRCP, DTMH, PhD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">David Mabey, BM, BCh, DM, FRCP</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Matthew Burton, PhD, MA, MBBCh, DTM&amp;H, MRCP, FRCOphth</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Emma Harding-Esch, BA(Hons), MPhil, MSc, PhD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Edward T Ryan, MD, DTMH</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Elinor L Baron, MD, DTMH</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jan 04, 2024.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H483986778"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Trachoma is the leading infectious cause of blindness worldwide [<a href="#rid1">1</a>]. It is a chronic keratoconjunctivitis caused by recurrent infection with <em>Chlamydia trachomatis</em> (a small, gram-negative obligate intracellular bacterium); humans are the only hosts. Trachoma is caused almost exclusively by <em>C. trachomatis</em> serotypes A, B, Ba, and C; genital infection is caused by serotypes D through K. (See  <a class="medical medical_review" href="/z/d/html/83019.html" rel="external">"Clinical manifestations and diagnosis of <i>Chlamydia trachomatis </i>infections"</a> and  <a class="medical medical_review" href="/z/d/html/7579.html" rel="external">"Treatment of <i>Chlamydia trachomatis</i> infection"</a>.)</p><p>The Alliance for the Global Elimination of Blinding Trachoma by the year 2020 (GET 2020) was established by the World Health Organization in 1997 and has helped to coordinate trachoma elimination efforts. The Neglected Tropical Disease road map 2021-2030 has set 2030 as the new target year for global elimination of trachoma as a public health problem. The Global Trachoma Mapping Project and its successor, Tropical Data, have established where current elimination efforts need to be concentrated [<a href="#rid2">2</a>].</p><p class="headingAnchor" id="H2450273870"><span class="h1">EPIDEMIOLOGY</span></p><p class="headingAnchor" id="H1867865243"><span class="h2">Geography and prevalence</span><span class="headingEndMark"> — </span>Trachoma is endemic in 40 countries [<a href="#rid3">3</a>] , largely in remote, resource-limited areas across Africa, Asia, Latin America, the Middle East, and the Pacific Rim  (<a class="graphic graphic_figure graphicRef117805" href="/z/d/graphic/117805.html" rel="external">figure 1</a>) [<a href="#rid4">4</a>].</p><p>The prevalence of active disease (characterized by follicles and/or severe inflammation of the upper tarsal conjunctiva) is highest in young children and declines to low levels in adulthood  (<a class="graphic graphic_figure graphicRef78281" href="/z/d/graphic/78281.html" rel="external">figure 2</a>). In endemic areas, it is common to be infected at least once (and often more than once) in childhood. In some studies, active disease has been observed in 60 percent of children &lt;5 years of age, and half of the bacterial load of <em>C. trachomatis</em> in the community may be found in children &lt;1 year of age [<a href="#rid5">5-7</a>]. A subgroup of children may have persistent, severe infection; these individuals are at risk for developing cicatricial (scarring) disease as older children and adults [<a href="#rid8">8,9</a>].</p><p>Trachoma may be associated with ocular pain and loss of vision, leading to loss of economic productivity and quality of life [<a href="#rid10">10</a>]. In 2023, an estimated 116 million people lived in districts in which the prevalence of active trachoma (trachomatous inflammation—follicular, TF) was ≥5 percent [<a href="#rid11">11</a>], and 1.5 million required surgery for trichiasis [<a href="#rid11">11</a>].</p><p>The number of individuals estimated to be affected by trachoma has declined in recent decades, likely due to trachoma elimination strategies as well as general improvements in hygiene standards. (See <a class="local">'Prevention'</a> below.)</p><p class="headingAnchor" id="H791487628"><span class="h2">Risk factors</span><span class="headingEndMark"> — </span>A number of environmental, socioeconomic, and behavioral factors have been associated with trachoma [<a href="#rid4">4,8,12</a>].</p><p>Factors associated with increased risk of trachoma include poor access to water and overcrowding (facilitating transfer of infected secretions) [<a href="#rid4">4,8,12</a>]. Scarring complications occur approximately two times more frequently in women than in men [<a href="#rid13">13</a>], which may reflect frequent contact with children (the primary reservoir of infection).</p><p>Factors associated with decreased risk of trachoma include facial cleanliness and reducing fly contact (via insecticide spraying, building latrines) [<a href="#rid8">8</a>]. Issues related to prevention of trachoma are discussed below. (See <a class="local">'Prevention'</a> below.)</p><p class="headingAnchor" id="H4024187862"><span class="h2">Transmission</span><span class="headingEndMark"> — </span><em>C. trachomatis</em> is highly infectious and transmitted directly or indirectly from eye to eye in areas of poor hygiene. <em>C. trachomatis</em> is thought to be transmitted between individuals via spread of ocular and nasal secretions on fingers and contaminated fomites [<a href="#rid14">14</a>]. Controlled laboratory experiments indicate that <em>C. trachomatis</em> remains viable for many hours on extraocular surfaces [<a href="#rid15">15</a>].  </p><p>In addition, transmission may occur via eye-seeking flies (such as <em>Musca sorbens</em>); in such cases, the flies serve as passive vectors but are not known to serve as reservoirs of infection [<a href="#rid12">12,14</a>].</p><p class="headingAnchor" id="H1352451163"><span class="h1">CLINICAL MANIFESTATIONS</span></p><p class="headingAnchor" id="H1683083576"><span class="h2">Disease phases</span><span class="headingEndMark"> — </span>The clinical manifestations of trachoma include two phases: active trachoma (conjunctivitis) and cicatricial disease (conjunctival scarring). In general, active trachoma occurs largely in young children; cicatricial disease and blindness occur in adults  (<a class="graphic graphic_figure graphicRef78281" href="/z/d/graphic/78281.html" rel="external">figure 2</a> and <a class="graphic graphic_figure graphicRef63925" href="/z/d/graphic/63925.html" rel="external">figure 3</a>) [<a href="#rid16">16</a>].</p><p>The clinical manifestations are used to categorize the severity of the disease in the simplified World Health Organization (WHO) trachoma grading system  (<a class="graphic graphic_table graphicRef54009" href="/z/d/graphic/54009.html" rel="external">table 1</a>), which was amended in 2020 to reflect changes in definitions and help users better understand and apply the definitions. The grading system can be used to guide management of individual patients and for screening programs. (See <a class="local">'Physical exam and grading system'</a> below.)</p><p class="headingAnchor" id="H3023046322"><span class="h3">Active trachoma (conjunctivitis)</span><span class="headingEndMark"> — </span>An initial isolated infection with <em>C. trachomatis</em> causes a mild, self-limited follicular conjunctivitis, best seen in the subtarsal conjunctiva of the everted upper eyelid  (<a class="graphic graphic_figure graphicRef54272" href="/z/d/graphic/54272.html" rel="external">figure 4</a>). Most patients with active trachoma are asymptomatic, even with marked signs of inflammation; for this reason, most cases of active trachoma are detected via screening programs  (<a class="graphic graphic_table graphicRef54009" href="/z/d/graphic/54009.html" rel="external">table 1</a>) [<a href="#rid17">17</a>]. Symptoms, if present, are typical of chronic conjunctivitis; they include redness, discomfort, light sensitivity, and mucopurulent discharge.</p><p>Findings of active trachoma are largely observed in children. Older individuals with <em>C. trachomatis</em> infection often do not display a follicular response but may develop a papillary reaction, particularly if there is secondary bacterial infection [<a href="#rid18">18</a>].</p><p>Individuals with repeated episodes of infection are at risk of developing scarring complications.</p><p class="headingAnchor" id="H2176762455"><span class="h3">Cicatricial disease (conjunctival scarring)</span><span class="headingEndMark"> — </span>The greater the severity and duration of active trachoma infection, the greater the likelihood of progression to cicatricial disease in adulthood [<a href="#rid19">19,20</a>]. Results from a four year cohort study in Tanzania suggested that the effect of infection on scarring progression is mediated through intense papillary conjunctival inflammation and that other factors contributing to inflammation, including connective tissue changes [<a href="#rid21">21</a>], may be important in driving conjunctival scarring progression in children [<a href="#rid22">22,23</a>]. </p><p>Repeated episodes of infection cause marked conjunctival inflammation, leading to eyelid scarring, as in panel A of the following picture  (<a class="graphic graphic_picture graphicRef54671" href="/z/d/graphic/54671.html" rel="external">picture 1</a>). A thick band near the lid margin (Arlt's line) may also be seen, as in panel B of the following picture  (<a class="graphic graphic_picture graphicRef54671" href="/z/d/graphic/54671.html" rel="external">picture 1</a>). These findings correspond with WHO grade trachomatous conjunctival scarring (TS)  (<a class="graphic graphic_table graphicRef54009" href="/z/d/graphic/54009.html" rel="external">table 1</a>). It is estimated that over &gt;100 conjunctival infections are needed during an individual's lifetime to develop conjunctival scarring [<a href="#rid24">24</a>]. </p><p>Eyelid scar tissue eventually contracts and can distort the lid margin leading to entropion (inward rolling of the eyelid) and trichiasis (eyelashes rubbing against the eyeball), as in panel A of the following picture  (<a class="graphic graphic_picture graphicRef62649" href="/z/d/graphic/62649.html" rel="external">picture 2</a>). These findings in the upper eyelid correlate with WHO grade trachomatous trichiasis (TT)  (<a class="graphic graphic_table graphicRef54009" href="/z/d/graphic/54009.html" rel="external">table 1</a>). An estimated 150 lifetime infections are thought to be required to lead to TT [<a href="#rid24">24</a>].</p><p>Individuals with TT have a greatly increased risk of blindness. TT is staged as minor (one to five eyelashes touching the eyeball) or major (six or more eyelashes touching the eyeball). Presence of TT should prompt surgical intervention. (See <a class="local">'Surgery for trichiasis'</a> below.)</p><p>Eyelash abrasion on the cornea leads to corneal edema, ulceration, and scarring. If untreated, corneal pannus (inflammatory vascular tissue) eventually develops, as in panel B in the following picture  (<a class="graphic graphic_picture graphicRef62649" href="/z/d/graphic/62649.html" rel="external">picture 2</a>), followed by corneal opacification, as in panel C in the following picture  (<a class="graphic graphic_picture graphicRef62649" href="/z/d/graphic/62649.html" rel="external">picture 2</a>), and loss of vision.</p><p class="headingAnchor" id="H2705120154"><span class="h2">Physical exam and grading system</span><span class="headingEndMark"> — </span>To grade the severity of disease, each eye should be examined with at least 2.5x loupe (magnifying lens) and a good flashlight with even illumination  (<a class="graphic graphic_figure graphicRef54272" href="/z/d/graphic/54272.html" rel="external">figure 4</a> and <a class="graphic graphic_picture graphicRef81505" href="/z/d/graphic/81505.html" rel="external">picture 3</a>). The conjunctiva should be evaluated for inflammation or discharge, and it should be noted whether eyelashes rub against the eyeball and whether eyelashes have been removed (epilated). The cornea should be examined for evidence of inflammation or opacification, and the upper eyelid should be everted to visualize the upper tarsal conjunctiva for evidence of follicles, inflammation, or scarring. Follicle size guides have been developed and are used in screening programs to help with the diagnosis of TF [<a href="#rid25">25</a>].</p><p>The WHO simplified grading system (amended in 2020) is summarized below and in the table  (<a class="graphic graphic_table graphicRef54009" href="/z/d/graphic/54009.html" rel="external">table 1</a>) [<a href="#rid26">26-28</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Trachomatous inflammation—follicular (TF) – Five or more follicles of ≥0.5 mm diameter in the central part of the upper tarsal conjunctiva, as in panel A in the following picture  (<a class="graphic graphic_picture graphicRef73800" href="/z/d/graphic/73800.html" rel="external">picture 4</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Trachomatous inflammation—intense (TI) – Papillary hypertrophy and inflammatory thickening of the upper tarsal conjunctiva obscuring more than half the deep tarsal vessels  (<a class="graphic graphic_picture graphicRef81505" href="/z/d/graphic/81505.html" rel="external">picture 3</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Trachomatous conjunctival scarring (TS) – Easily visible scars on the upper tarsal conjunctiva, as in panel A in the following picture  (<a class="graphic graphic_picture graphicRef54671" href="/z/d/graphic/54671.html" rel="external">picture 1</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Trachomatous trichiasis (TT) – At least one eyelash from the upper eyelid touching the eyeball or evidence of recent epilation (eyelash removal) of in-turned eyelashes from the upper eyelid, as in panel A in the following picture  (<a class="graphic graphic_picture graphicRef62649" href="/z/d/graphic/62649.html" rel="external">picture 2</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Corneal opacity (CO) – An easily visible corneal opacity that is so dense that at least part of the pupil margin is blurred when viewed through the opacity, as in panel C in the following picture  (<a class="graphic graphic_picture graphicRef62649" href="/z/d/graphic/62649.html" rel="external">picture 2</a>)</p><p></p><p>The major physical finding of active trachoma is the characteristic follicle on the superior tarsal conjunctiva  (<a class="graphic graphic_picture graphicRef73800" href="/z/d/graphic/73800.html" rel="external">picture 4</a>). The follicles are large, white or pale yellow foci of inflammatory material with a diameter of 0.5 to 2.0 mm, as in panel A in the following picture  (<a class="graphic graphic_picture graphicRef73800" href="/z/d/graphic/73800.html" rel="external">picture 4</a>). An individual with five or more follicles ≥0.5 mm in diameter in the central part of the upper tarsal conjunctiva should be categorized as WHO grade TF  (<a class="graphic graphic_table graphicRef54009" href="/z/d/graphic/54009.html" rel="external">table 1</a>). Papillae may appear alongside the follicles as pinpoint red dots but can become much larger and can coalesce to give the conjunctiva a thickened and edematous appearance, as in panel B in the following picture  (<a class="graphic graphic_picture graphicRef81505" href="/z/d/graphic/81505.html" rel="external">picture 3</a>). If papillary hypertrophy and inflammatory thickening obscure more than half of the deep tarsal vessels, WHO grade TI is present. In later disease, the follicles may leave grossly visible shallow pits in the cornea (Herbert's pits) that are pathognomonic for trachoma, as in panel B in the following picture  (<a class="graphic graphic_picture graphicRef73800" href="/z/d/graphic/73800.html" rel="external">picture 4</a>).</p><p>The signs in the simplified trachoma grading system are useful for decisions regarding public health interventions, such as mass drug administration with antibiotics. The 2020 amendment aims to ensure this system continues to be useful in estimating the burden of trachoma in population-based surveys to determine the need for further elimination measures. (See <a class="local">'Prevention'</a> below and <a class="local">'Mass antibiotic treatment'</a> below.)</p><p class="headingAnchor" id="H3469456037"><span class="h1">DIAGNOSIS</span><span class="headingEndMark"> — </span>The diagnosis of trachoma should be suspected in patients with follicular conjunctivitis and/or conjunctival scarring in areas where trachoma is endemic or in areas with risk for trachoma. (See <a class="local">'Epidemiology'</a> above.)</p><p>The diagnosis of trachoma is established based on the clinical signs [<a href="#rid26">26,28,29</a>]. Physical examination findings are used to categorize the severity of disease using the simplified grading system  (<a class="graphic graphic_table graphicRef54009" href="/z/d/graphic/54009.html" rel="external">table 1</a>) [<a href="#rid26">26,28</a>]. (See <a class="local">'Clinical manifestations'</a> above.)</p><p>As the prevalence of trachoma falls, the positive predictive value of clinical diagnosis decreases and the utility of microbiologic diagnosis increases [<a href="#rid30">30,31</a>]. In such settings, clinical signs of active trachoma are often present in the absence of active ocular <em>C. trachomatis</em> infection, particularly following mass drug administration [<a href="#rid32">32</a>]. Therefore, decisions to continue antibiotic distribution based solely on the prevalence of clinical signs may result in unnecessary antibiotic use, increasing the risk of macrolide resistance. </p><p>A 2021 World Health Organization (WHO) informal consultation on trachoma endgame challenges recommended that, in districts where TF prevalence has never fallen below the 5 percent elimination threshold ("persistent districts") or is not sustained below the 5 percent threshold at surveillance survey ("recrudescent districts"), tailored management be informed by <em>C. trachomatis</em> infection (diagnosed via nucleic acid amplification-based test [NAAT]) and/or anti-<em>C. trachomatis</em> antibody data [<a href="#rid33">33</a>].</p><p>NAATs are the most sensitive and specific diagnostic assays but are often prohibitively expensive and require expertise and resources that are not available in most endemic regions [<a href="#rid4">4</a>]. Novel isothermal NAATs requiring minimal technical expertise are being evaluated [<a href="#rid34">34</a>]. Other laboratory assays for diagnosis of <em>C. trachomatis</em> infection include direct immunofluorescent cytology, enzyme immunoassay, microscopy (Giemsa staining) of conjunctival samples, and tissue culture [<a href="#rid8">8</a>].</p><p>There is increasing interest in the use of serologic assays to measure antibody acquisition following exposure to <em>C. trachomatis</em>, which may be beneficial in identifying trends in population level transmission of public health significance. There would be potential application for this kind of diagnostic tool for programmatic surveillance, as trachoma-endemic areas near elimination targets [<a href="#rid35">35,36</a>]. Serologic data have been used to model seroconversion and seroreversion rates in trachoma-endemic settings to measure changes in transmission intensity [<a href="#rid37">37</a>]. Two antigens (pgp3 and CT694) have been proposed due to their correlation (at individual and population level) with clinical trachoma and ocular <em>C. trachomatis</em> infection [<a href="#rid38">38</a>]. </p><p class="headingAnchor" id="H1441252017"><span class="h1">DIFFERENTIAL DIAGNOSIS</span><span class="headingEndMark"> — </span>The differential diagnosis of trachoma depends on the stage of disease.</p><p>The differential diagnosis of conjunctivitis includes:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Viral conjunctivitis</strong> – Viral conjunctivitis causes red, irritated eyes with a gritty sensation. The tarsal conjunctiva may have a follicular appearance, and a tender, enlarged preauricular node may be present. Features that distinguish viral conjunctivitis from trachoma include a history of upper respiratory tract infection, rapid progression over several days, and the presence of a mucopurulent discharge. (See  <a class="medical medical_review" href="/z/d/html/6907.html" rel="external">"Conjunctivitis", section on 'Viral conjunctivitis'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Bacterial conjunctivitis</strong> – Patients with bacterial conjunctivitis present with redness and purulent discharge in one or both eyes. Discharge appears at the lid margins and corners of the eye, and more discharge appears within minutes of wiping the lids. Follicle formation is rare. (See  <a class="medical medical_review" href="/z/d/html/6907.html" rel="external">"Conjunctivitis", section on 'Bacterial conjunctivitis'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Allergic conjunctivitis</strong> – Allergic conjunctivitis is the most common cause of red, irritated, itchy eyes. Patients often have associated atopy and may suffer from eczema, hay fever, or asthma. A white, stringy discharge of mucus is common. Symptoms can be seasonal. The diagnosis is made clinically based on suggestive clinical history and consistent signs and symptoms. (See  <a class="medical medical_review" href="/z/d/html/5547.html" rel="external">"Allergic conjunctivitis: Clinical manifestations and diagnosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hypersensitivity conjunctivitis</strong> – Exposure to drugs, eye cosmetics, soaps, or other chemicals can lead to a hypersensitivity reaction that can appear follicular in nature. A detailed history is vital to identify and remove the causative agent. (See  <a class="medical medical_review" href="/z/d/html/6907.html" rel="external">"Conjunctivitis", section on 'Noninfectious, noninflammatory conjunctivitis'</a>.)</p><p></p><p>The differential diagnosis of cicatricial disease (conjunctival scarring) includes complications associated with bacterial conjunctivitis, trauma, or chalazion. (See  <a class="medical medical_review" href="/z/d/html/6898.html" rel="external">"Eyelid lesions", section on 'Chalazion'</a>.)</p><p class="headingAnchor" id="H890461627"><span class="h1">TREATMENT</span><span class="headingEndMark"> — </span>Treatment of trachoma consists of mass drug administration (MDA) of antibiotics to entire districts, with the aim of treating infection, interrupting transmission, and reducing the risk of repeated ocular infection with <em>C. trachomatis</em>. Patients with TT warrant surgery tailored to individual physical findings.</p><p class="headingAnchor" id="H3785817551"><span class="h2">Antibiotic therapy</span><span class="headingEndMark"> — </span>Antibiotic therapy for trachoma is best managed as MDA to an entire evaluation unit (EU), defined on the basis of resident population rather than on an individual basis. </p><p class="headingAnchor" id="H2845883501"><span class="h3">Antibiotic selection</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9041" href="/z/d/drug information/9041.html" rel="external">Azithromycin</a> (single dose 20 mg/kg orally, maximum 1 g) is given to all eligible members of an EU in MDA campaigns for trachoma elimination. Azithromycin is recommended since it is administered as a single oral dose; it is acceptable for use in children and for pregnant women [<a href="#rid39">39</a>]. Topical <a class="drug drug_general" data-topicid="9986" href="/z/d/drug information/9986.html" rel="external">tetracycline</a> (1% eye ointment twice daily for six weeks) can be used as an alternative, but adherence rates are likely to be very low. Our approach is consistent with the recommendations of the World Health Organization (WHO) [<a href="#rid40">40</a>].</p><p>The above approach is supported by randomized trials showing that a single dose of oral <a class="drug drug_general" data-topicid="9041" href="/z/d/drug information/9041.html" rel="external">azithromycin</a> is as effective as a long course of topical <a class="drug drug_general" data-topicid="9986" href="/z/d/drug information/9986.html" rel="external">tetracycline</a> for treatment of trachoma [<a href="#rid41">41-43</a>]. </p><p>Development of antibiotic resistance is a major concern with MDA. Chlamydial resistance to <a class="drug drug_general" data-topicid="9041" href="/z/d/drug information/9041.html" rel="external">azithromycin</a> has not been documented, although this may be due to difficulties associated with culturing the bacterium [<a href="#rid44">44</a>].</p><p>However, development of resistance in the setting of widespread antibiotic use has been described with other organisms [<a href="#rid44">44,45</a>], including development of <em>Streptococcus pneumoniae</em> resistance to <a class="drug drug_general" data-topicid="9041" href="/z/d/drug information/9041.html" rel="external">azithromycin</a> [<a href="#rid46">46-48</a>]. However, resistance appears to disappear within 12 months of MDA cessation [<a href="#rid44">44,48-50</a>].</p><p class="headingAnchor" id="H44880623"><span class="h3">Approach to mass treatment</span><span class="headingEndMark"> — </span>Antibiotic therapy for trachoma is best managed within an EU rather than on an individual basis, since <em>C. trachomatis</em> is highly infectious and transmitted rapidly in areas of poor hygiene [<a href="#rid30">30,40,44,51-56</a>]. Mass antibiotic treatment of a community reduces the reservoir of <em>C. trachomatis</em> infection [<a href="#rid44">44</a>].</p><p>We are in agreement with WHO guidelines, which recommend that an EU should undergo annual MDA for one year if the prevalence of TF among one to nine-year-old children (as assessed clinically) is 5 to 9.9 percent, for three years if the prevalence is 10 to 29.9 percent, and for five years if the prevalence is ≥30 percent [<a href="#rid57">57,58</a>]. (See <a class="local">'Physical exam and grading system'</a> above.)</p><p>For MDA, we favor oral <a class="drug drug_general" data-topicid="9041" href="/z/d/drug information/9041.html" rel="external">azithromycin</a> over topical <a class="drug drug_general" data-topicid="9986" href="/z/d/drug information/9986.html" rel="external">tetracycline</a> [<a href="#rid54">54,55</a>]. This approach is supported by a randomized trial including more than 1800 individuals in eight villages in The Gambia randomized to treatment with azithromycin (three doses at weekly intervals) or supervised topical tetracycline (daily for six weeks) [<a href="#rid55">55</a>]. Two months after treatment, the prevalence of trachoma was comparable (4.6 versus 5.1 percent, respectively); 12 months after treatment, the prevalence of trachoma was lower among those treated with azithromycin (7.7 versus 16 percent; adjusted odds ratio [OR] 0.52, 95% CI 0.34-0.80).</p><p>An impact survey should be conducted 6 to 12 months after the last planned round of MDA, to assess the TF prevalence in one to nine-year-olds; if ≥5 percent, additional MDA rounds are required [<a href="#rid59">59</a>]. Annual MDA should continue until the prevalence drops below 5 percent and this prevalence is sustained for at least two years measured by a surveillance survey; thereafter, MDA may be discontinued. </p><p>It is uncertain whether the strategy described above is always appropriate; in some reports, one or two treatments may be sufficient [<a href="#rid60">60,61</a>], and decline in the prevalence of clinical trachoma can lag behind the fall in the prevalence of infection detected by NAAT of conjunctival swabs [<a href="#rid62">62</a>]. In areas where the prevalence is greater than 50 percent, repeated MDA may be a viable tool for trachoma elimination [<a href="#rid63">63-66</a>]. However, in some settings, even many years of annual MDA appear insufficient to reduce the prevalence of TF to elimination levels [<a href="#rid67">67</a>]. As such, WHO has proposed tailored management strategies for persistent and recrudescent districts, including administration of mass treatment more frequently than annually [<a href="#rid33">33</a>].</p><p>In addition, it is uncertain whether there is benefit of biannual treatment over annual treatment. In one randomized trial including more than 14,000 individuals, biannual distribution was associated with lower trachoma prevalence than annual distribution (6.8 versus 0.9 percent) [<a href="#rid66">66</a>]. However, a subsequent randomized trial comparing annual with biannual <a class="drug drug_general" data-topicid="9041" href="/z/d/drug information/9041.html" rel="external">azithromycin</a> treatment noted comparable rates of infection at 18, 32, and 40 months following treatment [<a href="#rid61">61</a>]. Another trial observed that biannual treatment of children alone was comparable with annual treatment of the entire community [<a href="#rid68">68</a>]. </p><p>Attempting to eliminate <em>C. trachomatis</em> infection with antibiotics alone (in the absence of addressing underlying hygiene issues) is likely to lead to recurrence once antibiotic distribution ceases. (See <a class="local">'Environmental improvement'</a> below.)</p><p class="headingAnchor" id="H470026423"><span class="h3">Wider impact of mass treatment</span><span class="headingEndMark"> — </span>In addition to its benefit for trachoma, MDA with <a class="drug drug_general" data-topicid="9041" href="/z/d/drug information/9041.html" rel="external">azithromycin</a> has been associated with a reduction in childhood mortality in sub-Saharan Africa (in studies performed in Ethiopia, Niger, Malawi, and Tanzania) [<a href="#rid39">39,60,69-71</a>]. However, a study performed in Burkina Faso and Mali showed no benefit of adding azithromycin to seasonal malaria prophylaxis [<a href="#rid72">72</a>]. The trial data are discussed further below.</p><p>The significance of the findings, including longer-term effects and implications for health programs, requires clarification. Potential benefit of <a class="drug drug_general" data-topicid="9041" href="/z/d/drug information/9041.html" rel="external">azithromycin</a> may be attributable to the antimicrobial effect of azithromycin on gastrointestinal and respiratory pathogens and malaria infection; however, the mechanism is not fully understood. An important issue is the emergence of macrolide resistance with mass azithromycin administration, including in <em>S. pneumoniae </em>in the nasopharynx and <em>Escherichia coli</em> [<a href="#rid44">44,45,73</a>]. In a subsequent assessment of antibiotic resistance in communities that received azithromycin or placebo every 6 months for 4 years, determinants of macrolide resistance (based on stool metagenomic sequencing) were 7.5 times as high (95% CI 3.8-23.1) in the azithromycin group than the placebo group, suggesting that continued mass azithromycin distribution may propagate antibiotic resistance [<a href="#rid74">74</a>]. Further studies and careful consideration of the clinical impact of these findings need to be conducted to monitor the use of azithromycin in community MDA.</p><p>Notable trial data include: </p><p class="bulletIndent1"><span class="glyph">●</span>In a 2009 randomized trial in Ethiopia including 66,000 children aged one to nine years, mass administration of <a class="drug drug_general" data-topicid="9041" href="/z/d/drug information/9041.html" rel="external">azithromycin</a> (20 mg/kg single dose) was associated with a reduction in childhood mortality of 8.3 versus 4.1 per 1000 person years (OR 0.51, 95% CI 0.29-0.90) [<a href="#rid60">60</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a 2018 randomized trial including more than 190,000 children in Malawi, Niger, and Tanzania, mass distribution of <a class="drug drug_general" data-topicid="9041" href="/z/d/drug information/9041.html" rel="external">azithromycin</a> (biannual [six monthly] 20 mg/kg single dose) was associated with a 13 percent reduction in mortality in children aged 1 to 59 months compared with placebo (annual all-cause mortality rate 14.6 versus 16.5 per 1000 person-years) [<a href="#rid39">39</a>]. The greatest reduction in mortality was observed in Niger (18.1 percent) and among children aged one to five months. Mortality reductions in Malawi and Tanzania were 5.7 and 3.4 percent, respectively.</p><p></p><p class="bulletIndent1">In a longer term follow-up study by the same investigators, all communities received two additional open-label <a class="drug drug_general" data-topicid="9041" href="/z/d/drug information/9041.html" rel="external">azithromycin</a> distributions and no difference in mortality was observed between communities that received azithromycin for the first time and those that received it for a third year (24.0 versus 23.2 deaths per 1000 person-years), suggesting that the effect was not diminished by antimicrobial resistance [<a href="#rid69">69</a>]. </p><p></p><p class="bulletIndent1">In a further study of 700 Tanzanian children aged 1 to 36 months in thirty villages randomly assigned to biannual <a class="drug drug_general" data-topicid="9041" href="/z/d/drug information/9041.html" rel="external">azithromycin</a> (20 mg/kg single dose) or placebo followed for two years, no beneficial effect of azithromycin on diarrheal disease, acute respiratory illness, or anemia was observed [<a href="#rid75">75</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In contrast to the above studies, a randomized trial conducted in 2019 showed no benefit of adding <a class="drug drug_general" data-topicid="9041" href="/z/d/drug information/9041.html" rel="external">azithromycin</a> to seasonal malaria prophylaxis with respect to death or hospital admission; however, a lower disease burden was noted in the azithromycin arm [<a href="#rid72">72</a>]. The study included over 19,000 children in Burkina Faso and Mali; households were randomly assigned to receive azithromycin (three-day course) or placebo in addition to seasonal malaria prophylaxis (sulfadoxine-pyrimethamine and amodiaquine given at monthly intervals for four months of malaria transmission season for three years). There was no significant difference in the number of deaths or hospital admissions (24.8 versus 23.5 per 1000 person-years; incidence rate ratio 1.1, 95% CI 0.88-1.4). The effects of azithromycin alone, malaria prophylaxis alone, and placebo alone were not compared.</p><p></p><p class="headingAnchor" id="H1716772163"><span class="h2">Surgery for trichiasis</span><span class="headingEndMark"> — </span>The purpose of surgery is to stop the eyelashes from abrading the cornea, reduce ocular discharge, improve visual acuity, reduce progression to corneal opacity, and relieve discomfort.</p><p>For treatment of major trichiasis, we are in agreement with WHO recommends either bilamellar tarsal rotation (BLTR) or posterior lamellar tarsal rotation (PLTR). In one randomized trial including 1000 patients in Ethiopia who underwent PLTR or BLTR, one-year trichiasis recurrence rates were lower among those who underwent PLTR (22 versus 13 percent, respectively; adjusted OR 1.96, 95% CI 1.40-2.75) [<a href="#rid76">76,77</a>]. The patients enrolled in this trial were evaluated four years later; the PLTR surgical procedure had superior long-term outcomes in comparison to the BLTR, with significantly lower risk of postoperative recurrent TT [<a href="#rid78">78</a>]. Further operational study of PLTR would be beneficial. </p><p>For treatment of minor trichiasis, we favor surgery rather than epilation (eyelash removal) if an experienced surgeon is available. However, properly performed epilation with regular follow-up is a reasonable alternative to surgery for individuals who do not have access to surgery or who decline surgery [<a href="#rid79">79</a>]. In one randomized trial including patients with minor trichiasis in Oman randomized to treatment with BLTR, epilation via electrolysis or epilation via cryoablation, operative success was observed in 80, 29, and 18 percent of cases, respectively [<a href="#rid80">80</a>]. In a subsequent trial including 1300 patients with minor trichiasis in Ethiopia randomized to treatment with surgery or repeated epilation, vision and corneal opacity was comparable between the groups [<a href="#rid81">81</a>].</p><p>The role of antibiotics (<a class="drug drug_general" data-topicid="9041" href="/z/d/drug information/9041.html" rel="external">azithromycin</a>, <a class="drug drug_general" data-topicid="9393" href="/z/d/drug information/9393.html" rel="external">doxycycline</a>, or topical <a class="drug drug_general" data-topicid="9986" href="/z/d/drug information/9986.html" rel="external">tetracycline</a>) for prevention of recurrence following trichiasis surgery is uncertain [<a href="#rid82">82</a>]. The benefit of perioperative azithromycin may be greater in the setting of major trichiasis [<a href="#rid83">83-87</a>]. In one randomized trial including 451 patients in The Gambia with major or minor trichiasis who underwent surgery followed by randomization to azithromycin (single dose) or no treatment, there was no difference in the trichiasis recurrence rate (60 percent) between the azithromycin and control group at one year [<a href="#rid86">86</a>]. In a subsequent randomized trial including more than 1400 patients with trichiasis who underwent surgery followed by randomization to patient treatment with topical tetracycline (twice per day for six weeks), patient treatment with azithromycin (single dose), or patient and household treatment with azithromycin (single dose), the recurrence rate was lower among patients who received azithromycin than those who received topical tetracycline (7 versus 10 percent); there was no additional reduction in the arm that also treated household members [<a href="#rid87">87</a>]. Oral doxycycline (100 mg per day for four weeks) was not found to reduce recurrence in a randomized trial of 1000 people with trichiasis in Ethiopia [<a href="#rid88">88</a>].</p><p>The recurrence rate of trichiasis after surgery ranges from 5 to 60 percent in the first two to three years; the likelihood of recurrence increases with the severity of preoperative disease [<a href="#rid86">86,89-93</a>]. Recurrence may occur as part of the natural history of the initial disease or in association with repeat infection with further scarring. We favor repeat surgery for treatment of recurrent trichiasis, if feasible.</p><p>Challenges to successful implementation of a trichiasis surgery program include high rates of recurrent infection, limited resources for equipment, training and transportation, and patient barriers including limited understanding of the condition and potential benefits of surgery [<a href="#rid12">12,94</a>].</p><p class="headingAnchor" id="H4134036240"><span class="h1">PREVENTION</span><span class="headingEndMark"> — </span>The Neglected Tropical Diseases (NTD) Roadmap 2021-2030 targets trachoma for global elimination as a public health problem by 2030. The "SAFE" strategy is recommended to achieve this: <strong>S</strong>urgery for trichiasis, <strong>A</strong>ntibiotics (mass treatment with <a class="drug drug_general" data-topicid="9041" href="/z/d/drug information/9041.html" rel="external">azithromycin</a>) to clear <em>C. trachomatis</em> infection, <strong>F</strong>acial cleanliness, and <strong>E</strong>nvironmental improvement to limit transmission [<a href="#rid95">95</a>]. Eighteen countries are validated by WHO as having met the elimination targets [<a href="#rid96">96</a>].</p><p>Because blindness is irreversible, the strategy focuses on prevention. Surgical correction of TT prevents development of corneal opacification. Antibiotics, facial cleanliness, and environmental improvements can disrupt the cycle of reinfection.</p><p class="headingAnchor" id="H4125397739"><span class="h2">Surveillance</span><span class="headingEndMark"> — </span>Trachoma is defined as a public health problem by WHO when the prevalence of TF among one- to nine-year-old children (as assessed clinically) is ≥5 percent and/or the prevalence of TT among those aged 15 years or older is ≥0.2 percent [<a href="#rid12">12,97</a>].</p><p>The Global Trachoma Mapping Project completed a comprehensive trachoma surveying program, which has helped guide national trachoma elimination programs  (<a class="graphic graphic_figure graphicRef117805" href="/z/d/graphic/117805.html" rel="external">figure 1</a>) [<a href="#rid2">2,98</a>]. Its successor, Tropical Data, has continued to support baseline mapping and impact surveys to assess whether the elimination thresholds have been reached and surveillance surveys to determine whether the elimination thresholds have been maintained [<a href="#rid18">18</a>]. </p><p class="headingAnchor" id="H2697799793"><span class="h2">Mass antibiotic treatment</span><span class="headingEndMark"> — </span>Issues related to antibiotic therapy and mass treatment are discussed above. (See <a class="local">'Antibiotic therapy'</a> above.)</p><p class="headingAnchor" id="H3666644990"><span class="h2">Facial cleanliness</span><span class="headingEndMark"> — </span>Children with visible nasal discharge, ocular discharge, or flies on their faces are at least twice as likely to have active trachoma as children with clean faces [<a href="#rid99">99-101</a>]. However, it is unclear whether there is a causal relationship between dirty faces and trachoma, and facial cleanliness is difficult to measure in a standardized way [<a href="#rid102">102</a>]. Facial cleanliness is generally considered an important modifiable risk factor; water access and facial cleanliness are important factors in trachoma clustering in endemic regions [<a href="#rid103">103</a>]. Trachoma was once a major problem in Europe and North America; it disappeared from these areas as a result of improved living conditions rather than mass antibiotic distribution.</p><p>In one randomized trial including more than 1400 children in a trachoma-endemic area, villages were randomized to treatment with topical <a class="drug drug_general" data-topicid="9986" href="/z/d/drug information/9986.html" rel="external">tetracycline</a> ointment (30-day course) alone or in combination with an intensive community-based health education program to promote face washing [<a href="#rid104">104</a>]. The odds of developing severe active trachoma was lower in villages treated with received antibiotics and community-based health education than in villages treated with antibiotics alone (odds ratio 0.62, 95% CI 0.40-0.97).</p><p>In a study in Ethiopia, in the absence of antibiotic treatment, an integrated WASH (Water, Sanitation and Hygiene) intervention did not prevent resurgence of trachoma following cessation of antibiotics [<a href="#rid105">105</a>], suggesting that continued antibiotic treatment is required in settings with persistent trachoma, as part of the combined SAFE strategy. Further studies are required to improve the evidence base for WASH interventions for trachoma control.</p><p class="headingAnchor" id="H3075530091"><span class="h2">Environmental improvement</span><span class="headingEndMark"> — </span><em>C. trachomatis</em> is highly infectious and transmitted rapidly in areas of poor hygiene. Within a family, spread of infection can recur up to six months after <a class="drug drug_general" data-topicid="9041" href="/z/d/drug information/9041.html" rel="external">azithromycin</a> treatment; among families, spread of infection can occur in 12 months after antibiotic treatment [<a href="#rid51">51-53</a>].</p><p>Environmental improvement, including water, sanitation, and hygiene (WASH) are necessary for trachoma prevention and elimination [<a href="#rid106">106</a>]. Modifications in the availability and use of water and latrines, fly control, health education, and proximity to domesticated animals have all been proposed to reduce transmission of <em>C. trachomatis</em>. However, resources for implementation of such interventions in trachoma elimination programs are often limited [<a href="#rid12">12,107</a>]. The WHO WASH-NTD toolkit aims to support NTD programs to improve WASH services [<a href="#rid108">108</a>].</p><p>Environmental factors likely affect <em>C. trachomatis</em> transmission as a function of their influence on facial cleanliness [<a href="#rid109">109,110</a>]. Availability of clean water is a critical resource for facial cleanliness. In one study from Tanzania, the risk of trachoma in a household increased with distance from a water source; however, there was no association between trachoma risk and quantity of water brought into the house [<a href="#rid111">111</a>]. It may be that the distance between a home and its water supply influences a family's prioritization of water use for hygienic purposes. Thus, modifying the perception of how water should be used in the home may be at least as important as making water more accessible.</p><p>Eye to eye transmission of <em>C. trachomatis</em> may be interrupted if faces are kept free of ocular and nasal discharge by washing hands and faces. In one study including 83 children from Ethiopia aged 1 to 9 years with active trachoma allocated to a face cleaning protocol (face washing with water, face washing with water and soap, or face wiping), faces were examined for ocular and nasal discharge and swabs were taken from faces and hands to test for <em>C. trachomatis </em>at baseline, immediately post protocol, and 1, 2, and 4 hours afterwards [<a href="#rid112">112</a>]. Washing with soap was more effective at removing ocular discharge than washing with water (89 vs 27 percent of discharge removed, respectively) or face wiping (42 percent). </p><p>In a population-based household survey investigating the presence of extraocular <em>C. trachomatis</em> DNA within households, <em>C. trachomatis</em> DNA was detected on hands, faces, and clothing of individuals in households where active trachoma was present; in addition, <em>C. trachomatis </em>DNA was detected on flies in households where trachoma was present as well as in households where trachoma was absent, suggesting that flies may be a vector for transmission within and between infected and uninfected households [<a href="#rid14">14</a>]. A study using viability polymerase chain reaction to detect <em>C. trachomatis</em> supports the hypothesis that nonocular surfaces may have a role in the transmission of infection in trachoma [<a href="#rid15">15</a>].</p><p>Household fly density is a potentially amenable risk factor [<a href="#rid99">99</a>]. However, it is uncertain whether insecticide spraying is effective for reducing trachoma prevalence [<a href="#rid113">113,114</a>]. </p><p class="headingAnchor" id="H573640866"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span>Trachoma is the leading infectious cause of blindness worldwide  (<a class="graphic graphic_figure graphicRef117805" href="/z/d/graphic/117805.html" rel="external">figure 1</a>). It is a chronic keratoconjunctivitis caused by recurrent infection with <em>Chlamydia trachomatis</em>; humans are the only hosts. <em>C. trachomatis</em> is transmitted in areas of poor hygiene, probably via spread of ocular and nasal secretions on fingers and use of contaminated fomites. In addition, transmission may occur via eye-seeking flies (which serve as passive vectors but do not serve as reservoirs of infection). (See <a class="local">'Introduction'</a> above and <a class="local">'Epidemiology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The clinical manifestations of trachoma include two phases: active trachoma (conjunctivitis) and cicatricial disease (conjunctival scarring). In general, active trachoma occurs largely in young children; cicatricial disease and blindness occur in adults  (<a class="graphic graphic_figure graphicRef78281" href="/z/d/graphic/78281.html" rel="external">figure 2</a> and <a class="graphic graphic_figure graphicRef63925" href="/z/d/graphic/63925.html" rel="external">figure 3</a>). (See <a class="local">'Disease phases'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Initial <em>C. trachomatis</em> infection causes a mild, self-limited follicular conjunctivitis. Most patients with active trachoma are asymptomatic. For this reason, most cases of active trachoma are detected via screening programs. Symptoms, if present, are typical of chronic conjunctivitis; they include redness, discomfort, light sensitivity, and mucopurulent discharge. (See <a class="local">'Active trachoma (conjunctivitis)'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Repeated episodes of infection cause marked conjunctival inflammation, leading to eyelid scarring. Eyelid scar tissue eventually contracts and can distort the lid margin leading to entropion (inward rolling of the eyelid) and trichiasis (eyelashes rubbing against the eyeball). Individuals with trichiasis have a greatly increased risk of blindness. (See <a class="local">'Cicatricial disease (conjunctival scarring)'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The diagnosis of trachoma should be suspected in patients with follicular conjunctivitis and/or conjunctival scarring in areas where trachoma is endemic or in areas at risk for trachoma. The diagnosis is established based on the clinical manifestations. Physical examination findings are used to categorize the severity of disease using the World Health Organization (WHO) simplified grading system  (<a class="graphic graphic_table graphicRef54009" href="/z/d/graphic/54009.html" rel="external">table 1</a>). This grading system can be used to guide management of individual patients and for screening programs. (See <a class="local">'Physical exam and grading system'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Treatment of trachoma consists of antibiotic therapy; in addition, patients with trichiasis warrant surgery tailored to individual physical findings:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For districts with prevalence of TF ≥5 percent among one- to nine-year-old children, we suggest mass treatment with <a class="drug drug_general" data-topicid="9041" href="/z/d/drug information/9041.html" rel="external">azithromycin</a> (<a class="grade" href="https:///uptodate/show/grade_5" rel="external">Grade 2B</a>). Antibiotic therapy for trachoma is best managed within an entire region rather than on an individual basis. If the prevalence is &lt;5 percent, mass treatment is not needed. Azithromycin is preferred since it is administered as a single dose; topical <a class="drug drug_general" data-topicid="9986" href="/z/d/drug information/9986.html" rel="external">tetracycline</a> is an acceptable alternative. (See <a class="local">'Antibiotic selection'</a> above and <a class="local">'Approach to mass treatment'</a> above.) </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For surgical treatment of major trichiasis, procedures include bilamellar tarsal rotation or posterior lamellar tarsal rotation; the choice of approach depends on available expertise. For treatment of minor trichiasis, we suggest surgery over epilation (eyelash removal) (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'Surgery for trichiasis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>We are in agreement with the World Health Organization, which advocates the "SAFE" strategy for trachoma elimination: <strong>S</strong>urgery for trichiasis, <strong>A</strong>ntibiotics for <em>C. trachomatis</em> infection, <strong>F</strong>acial cleanliness, and <strong>E</strong>nvironmental improvement. Surgical correction of trichiasis prevents development of corneal opacification. Antibiotics, facial cleanliness, and environmental improvement can disrupt the cycle of reinfection. (See <a class="local">'Prevention'</a> above.)</p><p></p><p class="headingAnchor" id="H2532898594"><span class="h1">ACKNOWLEDGMENTS</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Heathcote Wright, PhD FRANZCO, Hugh Taylor, AC, MD, and Emily O'Kearney, MIPH, BPhty, who contributed to earlier versions of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li class="breakAll">World Health Organization. WHO Alliance for the Global Elimination of Trachoma by 2020: progress report on elimination of trachoma, 2020. https://reliefweb.int/sites/reliefweb.int/files/resources/WER9631-eng-fre.pdf (Accessed on September 20, 2021).</li><li><a class="nounderline abstract_t">Solomon AW, Pavluck AL, Courtright P, et al. The Global Trachoma Mapping Project: Methodology of a 34-Country Population-Based Study. Ophthalmic Epidemiol 2015; 22:214.</a></li><li class="breakAll">Weekly epidemiological record. World Health Organization, 2023. Available at: https://iris.who.int/bitstream/handle/10665/371094/WER9828-eng-fre.pdf (Accessed on November 14, 2023).</li><li class="breakAll">Taylor HR. Trachoma: A Blinding Scourge from the Bronze Age to the Twenty-first Century, Centre for Eye Research Australia, Melbourne 2008.</li><li><a class="nounderline abstract_t">Solomon AW, Holland MJ, Burton MJ, et al. Strategies for control of trachoma: observational study with quantitative PCR. Lancet 2003; 362:198.</a></li><li><a class="nounderline abstract_t">West SK, Munoz B, Turner VM, et al. The epidemiology of trachoma in central Tanzania. Int J Epidemiol 1991; 20:1088.</a></li><li><a class="nounderline abstract_t">Ngondi J, Onsarigo A, Adamu L, et al. The epidemiology of trachoma in Eastern Equatoria and Upper Nile States, southern Sudan. Bull World Health Organ 2005; 83:904.</a></li><li><a class="nounderline abstract_t">Taylor HR, Burton MJ, Haddad D, et al. Trachoma. Lancet 2014; 384:2142.</a></li><li><a class="nounderline abstract_t">Ramadhani AM, Derrick T, Holland MJ, Burton MJ. Blinding Trachoma: Systematic Review of Rates and Risk Factors for Progressive Disease. PLoS Negl Trop Dis 2016; 10:e0004859.</a></li><li><a class="nounderline abstract_t">Habtamu E, Wondie T, Aweke S, et al. Impact of Trichiasis Surgery on Quality of Life: A Longitudinal Study in Ethiopia. PLoS Negl Trop Dis 2016; 10:e0004627.</a></li><li class="breakAll">World Health Organization. WHO Alliance for the Global Elimination of Trachoma: progress report on elimination of trachoma, 2021. https://apps.who.int/iris/bitstream/handle/10665/361290/WER9731-eng-fre.pdf (Accessed on November 09, 2022).</li><li><a class="nounderline abstract_t">Hu VH, Harding-Esch EM, Burton MJ, et al. Epidemiology and control of trachoma: systematic review. Trop Med Int Health 2010; 15:673.</a></li><li><a class="nounderline abstract_t">Cromwell EA, Courtright P, King JD, et al. The excess burden of trachomatous trichiasis in women: a systematic review and meta-analysis. Trans R Soc Trop Med Hyg 2009; 103:985.</a></li><li><a class="nounderline abstract_t">Last A, Versteeg B, Shafi Abdurahman O, et al. Detecting extra-ocular Chlamydia trachomatis in a trachoma-endemic community in Ethiopia: Identifying potential routes of transmission. PLoS Negl Trop Dis 2020; 14:e0008120.</a></li><li><a class="nounderline abstract_t">Versteeg B, Vasileva H, Houghton J, et al. Viability PCR shows that non-ocular surfaces could contribute to transmission of Chlamydia trachomatis infection in trachoma. PLoS Negl Trop Dis 2020; 14:e0008449.</a></li><li><a class="nounderline abstract_t">Taylor HR, Siler JA, Mkocha HA, et al. The natural history of endemic trachoma: a longitudinal study. Am J Trop Med Hyg 1992; 46:552.</a></li><li><a class="nounderline abstract_t">Solomon AW, Peeling RW, Foster A, Mabey DC. Diagnosis and assessment of trachoma. Clin Microbiol Rev 2004; 17:982.</a></li><li><a class="nounderline abstract_t">Solomon AW, Burton MJ, Gower EW, et al. Trachoma. Nat Rev Dis Primers 2022; 8:32.</a></li><li><a class="nounderline abstract_t">West SK, Muñoz B, Mkocha H, et al. Progression of active trachoma to scarring in a cohort of Tanzanian children. Ophthalmic Epidemiol 2001; 8:137.</a></li><li><a class="nounderline abstract_t">Bobo LD, Novak N, Muñoz B, et al. Severe disease in children with trachoma is associated with persistent Chlamydia trachomatis infection. J Infect Dis 1997; 176:1524.</a></li><li><a class="nounderline abstract_t">Hoffman JJ, Massae P, Weiss HA, et al. In vivo confocal microscopy and trachomatous conjunctival scarring: Predictors for clinical progression. Clin Exp Ophthalmol 2020; 48:1152.</a></li><li><a class="nounderline abstract_t">Derrick T, Ramadhani AM, Macleod D, et al. Immunopathogenesis of Progressive Scarring Trachoma: Results of a 4-Year Longitudinal Study in Tanzanian Children. Infect Immun 2020; 88.</a></li><li><a class="nounderline abstract_t">Ramadhani AM, Derrick T, Macleod D, et al. Progression of scarring trachoma in Tanzanian children: A four-year cohort study. PLoS Negl Trop Dis 2019; 13:e0007638.</a></li><li><a class="nounderline abstract_t">Gambhir M, Basáñez MG, Burton MJ, et al. The development of an age-structured model for trachoma transmission dynamics, pathogenesis and control. PLoS Negl Trop Dis 2009; 3:e462.</a></li><li><a class="nounderline abstract_t">Solomon AW, Le Mesurier RT, Williams WJ. A diagnostic instrument to help field graders evaluate active trachoma. Ophthalmic Epidemiol 2018; 25:399.</a></li><li><a class="nounderline abstract_t">Thylefors B, Dawson CR, Jones BR, et al. A simple system for the assessment of trachoma and its complications. Bull World Health Organ 1987; 65:477.</a></li><li><a class="nounderline abstract_t">Taylor HR, West SK, Katala S, Foster A. Trachoma: evaluation of a new grading scheme in the United Republic of Tanzania. Bull World Health Organ 1987; 65:485.</a></li><li><a class="nounderline abstract_t">Solomon AW, Kello AB, Bangert M, et al. The simplified trachoma grading system, amended. Bull World Health Organ 2020; 98:698.</a></li><li><a class="nounderline abstract_t">Dawson CR, Jones BR, Darougar S. Blinding and non-blinding trachoma: assessment of intensity of upper tarsal inflammatory disease and disabling lesions. Bull World Health Organ 1975; 52:279.</a></li><li><a class="nounderline abstract_t">Solomon AW, Holland MJ, Alexander ND, et al. Mass treatment with single-dose azithromycin for trachoma. N Engl J Med 2004; 351:1962.</a></li><li><a class="nounderline abstract_t">Wright HR, Taylor HR. Clinical examination and laboratory tests for estimation of trachoma prevalence in a remote setting: what are they really telling us? Lancet Infect Dis 2005; 5:313.</a></li><li><a class="nounderline abstract_t">Ramadhani AM, Derrick T, Macleod D, et al. The Relationship between Active Trachoma and Ocular Chlamydia trachomatis Infection before and after Mass Antibiotic Treatment. PLoS Negl Trop Dis 2016; 10:e0005080.</a></li><li class="breakAll">World Health Organization. Informal consultation on end-game challenges for trachoma elimination, Task Force for Global Health, Decatur, United States of America, 7–9 December 2021. https://apps.who.int/iris/handle/10665/363591 (Accessed on November 09, 2022).</li><li><a class="nounderline abstract_t">Derrick TR, Sandetskaya N, Pickering H, et al. DjinniChip: evaluation of a novel molecular rapid diagnostic device for the detection of Chlamydia trachomatis in trachoma-endemic areas. Parasit Vectors 2020; 13:533.</a></li><li><a class="nounderline abstract_t">Martin DL, Saboyà-Díaz MI, Abashawl A, et al. The use of serology for trachoma surveillance: Current status and priorities for future investigation. PLoS Negl Trop Dis 2020; 14:e0008316.</a></li><li><a class="nounderline abstract_t">Tedijanto C, Solomon AW, Martin DL, et al. Monitoring transmission intensity of trachoma with serology. Nat Commun 2023; 14:3269.</a></li><li><a class="nounderline abstract_t">Pinsent A, Solomon AW, Bailey RL, et al. The utility of serology for elimination surveillance of trachoma. Nat Commun 2018; 9:5444.</a></li><li><a class="nounderline abstract_t">Goodhew EB, Priest JW, Moss DM, et al. CT694 and pgp3 as serological tools for monitoring trachoma programs. PLoS Negl Trop Dis 2012; 6:e1873.</a></li><li><a class="nounderline abstract_t">Keenan JD, Bailey RL, West SK, et al. Azithromycin to Reduce Childhood Mortality in Sub-Saharan Africa. N Engl J Med 2018; 378:1583.</a></li><li class="breakAll">Solomon AW, Zondervan M, Kuper H, et al. Trachoma control: A guide for programme managers. World Health Organization, Geneva 2006. http://apps.who.int/iris/bitstream/10665/43405/1/9241546905_eng.pdf (Accessed on October 27, 2016).</li><li><a class="nounderline abstract_t">Bailey RL, Arullendran P, Whittle HC, Mabey DC. Randomised controlled trial of single-dose azithromycin in treatment of trachoma. Lancet 1993; 342:453.</a></li><li><a class="nounderline abstract_t">Dawson CR, Schachter J, Sallam S, et al. A comparison of oral azithromycin with topical oxytetracycline/polymyxin for the treatment of trachoma in children. Clin Infect Dis 1997; 24:363.</a></li><li><a class="nounderline abstract_t">Tabbara KF, Abu-el-Asrar A, al-Omar O, et al. Single-dose azithromycin in the treatment of trachoma. A randomized, controlled study. Ophthalmology 1996; 103:842.</a></li><li><a class="nounderline abstract_t">Evans JR, Solomon AW, Kumar R, et al. Antibiotics for trachoma. Cochrane Database Syst Rev 2019; 9:CD001860.</a></li><li><a class="nounderline abstract_t">O'Brien KS, Emerson P, Hooper PJ, et al. Antimicrobial resistance following mass azithromycin distribution for trachoma: a systematic review. Lancet Infect Dis 2019; 19:e14.</a></li><li><a class="nounderline abstract_t">Chern KC, Shrestha SK, Cevallos V, et al. Alterations in the conjunctival bacterial flora following a single dose of azithromycin in a trachoma endemic area. Br J Ophthalmol 1999; 83:1332.</a></li><li><a class="nounderline abstract_t">Leach AJ, Shelby-James TM, Mayo M, et al. A prospective study of the impact of community-based azithromycin treatment of trachoma on carriage and resistance of Streptococcus pneumoniae. Clin Infect Dis 1997; 24:356.</a></li><li><a class="nounderline abstract_t">Coles CL, Mabula K, Seidman JC, et al. Mass distribution of azithromycin for trachoma control is associated with increased risk of azithromycin-resistant Streptococcus pneumoniae carriage in young children 6 months after treatment. Clin Infect Dis 2013; 56:1519.</a></li><li><a class="nounderline abstract_t">Gaynor BD, Holbrook KA, Whitcher JP, et al. Community treatment with azithromycin for trachoma is not associated with antibiotic resistance in Streptococcus pneumoniae at 1 year. Br J Ophthalmol 2003; 87:147.</a></li><li><a class="nounderline abstract_t">Ho DK, Sawicki C, Grassly N. Antibiotic Resistance in Streptococcus pneumoniae after Azithromycin Distribution for Trachoma. J Trop Med 2015; 2015:917370.</a></li><li><a class="nounderline abstract_t">West SK, Munoz B, Mkocha H, et al. Infection with Chlamydia trachomatis after mass treatment of a trachoma hyperendemic community in Tanzania: a longitudinal study. Lancet 2005; 366:1296.</a></li><li><a class="nounderline abstract_t">Burton MJ, Holland MJ, Faal N, et al. Which members of a community need antibiotics to control trachoma? Conjunctival Chlamydia trachomatis infection load in Gambian villages. Invest Ophthalmol Vis Sci 2003; 44:4215.</a></li><li><a class="nounderline abstract_t">Atik B, Thanh TT, Luong VQ, et al. Impact of annual targeted treatment on infectious trachoma and susceptibility to reinfection. JAMA 2006; 296:1488.</a></li><li><a class="nounderline abstract_t">Schachter J, West SK, Mabey D, et al. Azithromycin in control of trachoma. Lancet 1999; 354:630.</a></li><li><a class="nounderline abstract_t">Fraser-Hurt N, Bailey RL, Cousens S, et al. Efficacy of oral azithromycin versus topical tetracycline in mass treatment of endemic trachoma. Bull World Health Organ 2001; 79:632.</a></li><li><a class="nounderline abstract_t">West ES, Munoz B, Mkocha H, et al. Mass treatment and the effect on the load of Chlamydia trachomatis infection in a trachoma-hyperendemic community. Invest Ophthalmol Vis Sci 2005; 46:83.</a></li><li class="breakAll">World Health Organization. Report of the 3rd global scientific meeting on trachoma elimination, 2010. https://apps.who.int/iris/bitstream/handle/10665/329074/WHO-PBD-2.10-eng.pdf?sequence=1&amp;isAllowed=y (Accessed on December 31, 2017).</li><li class="breakAll">Trachoma Control A guide for Programme Managers. Geneva, Switzerland: World Health Organization; 2006. https://apps.who.int/iris/handle/10665/43405 (Accessed on October 27, 2021).</li><li class="breakAll">World Health Organization. Validation of elimination of trachoma as a public health problem. https://apps.who.int/iris/bitstream/handle/10665/208901/WHO-HTM-NTD-2016.8-eng.pdf?sequence=1&amp;isAllowed=y (Accessed on October 13, 2021).</li><li><a class="nounderline abstract_t">Porco TC, Gebre T, Ayele B, et al. Effect of mass distribution of azithromycin for trachoma control on overall mortality in Ethiopian children: a randomized trial. JAMA 2009; 302:962.</a></li><li><a class="nounderline abstract_t">Gebre T, Ayele B, Zerihun M, et al. Comparison of annual versus twice-yearly mass azithromycin treatment for hyperendemic trachoma in Ethiopia: a cluster-randomised trial. Lancet 2012; 379:143.</a></li><li><a class="nounderline abstract_t">Solomon AW, Harding-Esch E, Alexander ND, et al. Two doses of azithromycin to eliminate trachoma in a Tanzanian community. N Engl J Med 2008; 358:1870.</a></li><li><a class="nounderline abstract_t">Lietman T, Porco T, Dawson C, Blower S. Global elimination of trachoma: how frequently should we administer mass chemotherapy? Nat Med 1999; 5:572.</a></li><li><a class="nounderline abstract_t">Melese M, Chidambaram JD, Alemayehu W, et al. Feasibility of eliminating ocular Chlamydia trachomatis with repeat mass antibiotic treatments. JAMA 2004; 292:721.</a></li><li><a class="nounderline abstract_t">Gill DA, Lakew T, Alemayehu W, et al. Complete elimination is a difficult goal for trachoma programs in severely affected communities. Clin Infect Dis 2008; 46:564.</a></li><li><a class="nounderline abstract_t">Melese M, Alemayehu W, Lakew T, et al. Comparison of annual and biannual mass antibiotic administration for elimination of infectious trachoma. JAMA 2008; 299:778.</a></li><li><a class="nounderline abstract_t">Sata E, Nute AW, Astale T, et al. Twelve-Year Longitudinal Trends in Trachoma Prevalence among Children Aged 1-9 Years in Amhara, Ethiopia, 2007-2019. Am J Trop Med Hyg 2021; 104:1278.</a></li><li><a class="nounderline abstract_t">Amza A, Kadri B, Nassirou B, et al. A Cluster-Randomized Trial to Assess the Efficacy of Targeting Trachoma Treatment to Children. Clin Infect Dis 2017; 64:743.</a></li><li><a class="nounderline abstract_t">Keenan JD, Arzika AM, Maliki R, et al. Longer-Term Assessment of Azithromycin for Reducing Childhood Mortality in Africa. N Engl J Med 2019; 380:2207.</a></li><li><a class="nounderline abstract_t">See CW, O'Brien KS, Keenan JD, et al. The Effect of Mass Azithromycin Distribution on Childhood Mortality: Beliefs and Estimates of Efficacy. Am J Trop Med Hyg 2015; 93:1106.</a></li><li><a class="nounderline abstract_t">Keenan JD, Ayele B, Gebre T, et al. Childhood mortality in a cohort treated with mass azithromycin for trachoma. Clin Infect Dis 2011; 52:883.</a></li><li><a class="nounderline abstract_t">Chandramohan D, Dicko A, Zongo I, et al. Effect of Adding Azithromycin to Seasonal Malaria Chemoprevention. N Engl J Med 2019; 380:2197.</a></li><li><a class="nounderline abstract_t">Doan T, Arzika AM, Hinterwirth A, et al. Macrolide Resistance in MORDOR I - A Cluster-Randomized Trial in Niger. N Engl J Med 2019; 380:2271.</a></li><li><a class="nounderline abstract_t">Doan T, Worden L, Hinterwirth A, et al. Macrolide and Nonmacrolide Resistance with Mass Azithromycin Distribution. N Engl J Med 2020; 383:1941.</a></li><li><a class="nounderline abstract_t">West SK, Bloch E, Weaver J, et al. Morbidity in a Longitudinal Cohort of Children Residing in Villages Randomized to Biannual Treatment With Azithromycin Versus Placebo. Clin Infect Dis 2020; 70:574.</a></li><li><a class="nounderline abstract_t">Habtamu E, Wondie T, Aweke S, et al. Posterior lamellar versus bilamellar tarsal rotation surgery for trachomatous trichiasis in Ethiopia: a randomised controlled trial. Lancet Glob Health 2016; 4:e175.</a></li><li><a class="nounderline abstract_t">Solomon AW. Optimising the management of trachomatous trichiasis. Lancet Glob Health 2016; 4:e140.</a></li><li><a class="nounderline abstract_t">Habtamu E, Wondie T, Tadesse Z, et al. Posterior lamellar versus bilamellar tarsal rotation surgery for trachomatous trichiasis: Long-term outcomes from a randomised controlled trial. EClinicalMedicine 2019; 17:100202.</a></li><li><a class="nounderline abstract_t">Habtamu E, Rajak SN, Tadesse Z, et al. Epilation for minor trachomatous trichiasis: four-year results of a randomised controlled trial. PLoS Negl Trop Dis 2015; 9:e0003558.</a></li><li><a class="nounderline abstract_t">Reacher MH, Muñoz B, Alghassany A, et al. A controlled trial of surgery for trachomatous trichiasis of the upper lid. Arch Ophthalmol 1992; 110:667.</a></li><li><a class="nounderline abstract_t">Rajak SN, Habtamu E, Weiss HA, et al. Surgery versus epilation for the treatment of minor trichiasis in Ethiopia: a randomised controlled noninferiority trial. PLoS Med 2011; 8:e1001136.</a></li><li class="breakAll">Reacher M, Foster A, Huber J. Trichiasis surgery for trachoma: the bilamellar tarsal rotation procedure. World Health Organization, Geneva 1998. http://apps.who.int/iris/bitstream/10665/62064/1/WHO_PBL_93.29.pdf (Accessed on October 27, 2016).</li><li><a class="nounderline abstract_t">West S, Alemayehu W, Munoz B, Gower EW. Azithromycin prevents recurrence of severe trichiasis following trichiasis surgery: STAR trial. Ophthalmic Epidemiol 2007; 14:273.</a></li><li><a class="nounderline abstract_t">Zhang H, Kandel RP, Atakari HK, Dean D. Impact of oral azithromycin on recurrence of trachomatous trichiasis in Nepal over 1 year. Br J Ophthalmol 2006; 90:943.</a></li><li><a class="nounderline abstract_t">Woreta F, Munoz B, Gower E, et al. Three-year outcomes of the surgery for trichiasis, antibiotics to prevent recurrence trial. Arch Ophthalmol 2012; 130:427.</a></li><li><a class="nounderline abstract_t">Burton MJ, Kinteh F, Jallow O, et al. A randomised controlled trial of azithromycin following surgery for trachomatous trichiasis in the Gambia. Br J Ophthalmol 2005; 89:1282.</a></li><li><a class="nounderline abstract_t">West SK, West ES, Alemayehu W, et al. Single-dose azithromycin prevents trichiasis recurrence following surgery: randomized trial in Ethiopia. Arch Ophthalmol 2006; 124:309.</a></li><li><a class="nounderline abstract_t">Habtamu E, Wondie T, Aweke S, et al. Oral doxycycline for the prevention of postoperative trachomatous trichiasis in Ethiopia: a randomised, double-blind, placebo-controlled trial. Lancet Glob Health 2018; 6:e579.</a></li><li><a class="nounderline abstract_t">Bog H, Yorston D, Foster A. Results of community-based eyelid surgery for trichiasis due to trachoma. Br J Ophthalmol 1993; 77:81.</a></li><li><a class="nounderline abstract_t">Bowman RJ, Jatta B, Faal H, et al. Long-term follow-up of lid surgery for trichiasis in the Gambia: surgical success and patient perceptions. Eye (Lond) 2000; 14:864.</a></li><li><a class="nounderline abstract_t">Khandekar R, Mohammed AJ, Courtright P. Recurrence of trichiasis: a long-term follow-up study in the Sultanate of Oman. Ophthalmic Epidemiol 2001; 8:155.</a></li><li><a class="nounderline abstract_t">Thanh TT, Khandekar R, Luong VQ, Courtright P. One year recurrence of trachomatous trichiasis in routinely operated Cuenod Nataf procedure cases in Vietnam. Br J Ophthalmol 2004; 88:1114.</a></li><li><a class="nounderline abstract_t">Burton MJ, Bowman RJ, Faal H, et al. Long term outcome of trichiasis surgery in the Gambia. Br J Ophthalmol 2005; 89:575.</a></li><li><a class="nounderline abstract_t">Bhosai SJ, Bailey RL, Gaynor BD, Lietman TM. Trachoma:  an update on prevention, diagnosis, and treatment. Curr Opin Ophthalmol 2012; 23:288.</a></li><li class="breakAll">Global elimination of blinding trachoma. World Health Assembly Resolution WHA 51.11. World Health Organization, Geneva 1998. http://www.who.int/neglected_diseases/mediacentre/WHA_51.11_Eng.pdf (Accessed on December 21, 2017).</li><li class="breakAll">https://www.trachomacoalition.org/trachomastatistics (Accessed on December 13, 2023).</li><li class="breakAll">Planning for the Global Elimination of Trachoma (GET). World Health Organization, Geneva 1997.</li><li class="breakAll">Trachoma Atlas. http://www.trachomaatlas.org/ (Accessed on August 29, 2016).</li><li><a class="nounderline abstract_t">Taylor HR, West SK, Mmbaga BB, et al. Hygiene factors and increased risk of trachoma in central Tanzania. Arch Ophthalmol 1989; 107:1821.</a></li><li><a class="nounderline abstract_t">Hsieh YH, Bobo LD, Quinn TC, West SK. Risk factors for trachoma: 6-year follow-up of children aged 1 and 2 years. Am J Epidemiol 2000; 152:204.</a></li><li><a class="nounderline abstract_t">Ejere HO, Alhassan MB, Rabiu M. Face washing promotion for preventing active trachoma. Cochrane Database Syst Rev 2015; :CD003659.</a></li><li><a class="nounderline abstract_t">Harding-Esch EM, Holland MJ, Schémann JF, et al. Facial cleanliness indicators by time of day: results of a cross-sectional trachoma prevalence survey in Senegal. Parasit Vectors 2020; 13:556.</a></li><li><a class="nounderline abstract_t">Altherr FM, Nute AW, Zerihun M, et al. Associations between Water, Sanitation and Hygiene (WASH) and trachoma clustering at aggregate spatial scales, Amhara, Ethiopia. Parasit Vectors 2019; 12:540.</a></li><li><a class="nounderline abstract_t">West S, Muñoz B, Lynch M, et al. Impact of face-washing on trachoma in Kongwa, Tanzania. Lancet 1995; 345:155.</a></li><li><a class="nounderline abstract_t">Solomon Aragie, Dionna M Wittberg, Wondyifraw Tadesse, et al. Water, sanitation, and hygiene for control of trachoma in Ethiopia (WUHA): a two-arm, parallel-group, cluster-randomised trial. Lancet 2022; 10:87.</a></li><li class="breakAll">Hamilton H, Velleman Y. WASHing away blinding trachoma. Sightsavers, West Sussex, UK 2013. http://www.who.int/blindness/causes/WASHing_away_blinding_trachoma.pdf (Accessed on August 29, 2016).</li><li><a class="nounderline abstract_t">Rabiu M, Alhassan MB, Ejere HO, Evans JR. Environmental sanitary interventions for preventing active trachoma. Cochrane Database Syst Rev 2012; :CD004003.</a></li><li class="breakAll">World Health Organization. WASH and Health working together: A ‘HOW-TO’ GUIDE FOR NEGLECTED TROPICAL DISEASE PROGRAMMES. https://apps.who.int/iris/bitstream/handle/10665/279913/9789241515009-eng.pdf?sequence=1&amp;isAllowed=y (Accessed on October 13, 2021).</li><li class="breakAll">Taylor HR. A Blinding Scourge from the Bronze Age to the Twenty-first Century, Centre for Eye Research Australia, Melbourne 2008.</li><li><a class="nounderline abstract_t">Stocks ME, Ogden S, Haddad D, et al. Effect of water, sanitation, and hygiene on the prevention of trachoma: a systematic review and meta-analysis. PLoS Med 2014; 11:e1001605.</a></li><li><a class="nounderline abstract_t">West S, Lynch M, Turner V, et al. Water availability and trachoma. Bull World Health Organ 1989; 67:71.</a></li><li><a class="nounderline abstract_t">Czerniewska A, Versteeg A, Shafi O, et al. Comparison of Face Washing and Face Wiping Methods for Trachoma Control: A Pilot Study. Am J Trop Med Hyg 2020; 102:740.</a></li><li><a class="nounderline abstract_t">West SK, Emerson PM, Mkocha H, et al. Intensive insecticide spraying for fly control after mass antibiotic treatment for trachoma in a hyperendemic setting: a randomised trial. Lancet 2006; 368:596.</a></li><li><a class="nounderline abstract_t">Emerson PM, Lindsay SW, Alexander N, et al. Role of flies and provision of latrines in trachoma control: cluster-randomised controlled trial. Lancet 2004; 363:1093.</a></li></ol></div><div id="topicVersionRevision">Topic 3026 Version 40.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://reliefweb.int/sites/reliefweb.int/files/resources/WER9631-eng-fre.pdf" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : World Health Organization. WHO Alliance for the Global Elimination of Trachoma by 2020: progress report on elimination of trachoma, 2020. https://reliefweb.int/sites/reliefweb.int/files/resources/WER9631-eng-fre.pdf (Accessed on September 20, 2021).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26158580" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : The Global Trachoma Mapping Project: Methodology of a 34-Country Population-Based Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26158580" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : The Global Trachoma Mapping Project: Methodology of a 34-Country Population-Based Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26158580" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : The Global Trachoma Mapping Project: Methodology of a 34-Country Population-Based Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12885481" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Strategies for control of trachoma: observational study with quantitative PCR.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1800408" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : The epidemiology of trachoma in central Tanzania.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16462982" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : The epidemiology of trachoma in Eastern Equatoria and Upper Nile States, southern Sudan.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25043452" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Trachoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27483002" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Blinding Trachoma: Systematic Review of Rates and Risk Factors for Progressive Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27078493" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Impact of Trichiasis Surgery on Quality of Life: A Longitudinal Study in Ethiopia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27078493" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Impact of Trichiasis Surgery on Quality of Life: A Longitudinal Study in Ethiopia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20374566" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Epidemiology and control of trachoma: systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19362326" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : The excess burden of trachomatous trichiasis in women: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32130213" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Detecting extra-ocular Chlamydia trachomatis in a trachoma-endemic community in Ethiopia: Identifying potential routes of transmission.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32667914" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Viability PCR shows that non-ocular surfaces could contribute to transmission of Chlamydia trachomatis infection in trachoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1599049" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : The natural history of endemic trachoma: a longitudinal study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15489358" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Diagnosis and assessment of trachoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35618795" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Trachoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11471083" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Progression of active trachoma to scarring in a cohort of Tanzanian children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9395364" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Severe disease in children with trachoma is associated with persistent Chlamydia trachomatis infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32798249" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : In vivo confocal microscopy and trachomatous conjunctival scarring: Predictors for clinical progression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31964744" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Immunopathogenesis of Progressive Scarring Trachoma: Results of a 4-Year Longitudinal Study in Tanzanian Children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31412025" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Progression of scarring trachoma in Tanzanian children: A four-year cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19529762" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : The development of an age-structured model for trachoma transmission dynamics, pathogenesis and control.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30067432" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : A diagnostic instrument to help field graders evaluate active trachoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3500800" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : A simple system for the assessment of trachoma and its complications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3500801" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Trachoma: evaluation of a new grading scheme in the United Republic of Tanzania.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33177759" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : The simplified trachoma grading system, amended.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1084798" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Blinding and non-blinding trachoma: assessment of intensity of upper tarsal inflammatory disease and disabling lesions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15525721" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Mass treatment with single-dose azithromycin for trachoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15854887" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Clinical examination and laboratory tests for estimation of trachoma prevalence in a remote setting: what are they really telling us?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27783678" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : The Relationship between Active Trachoma and Ocular Chlamydia trachomatis Infection before and after Mass Antibiotic Treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27783678" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : The Relationship between Active Trachoma and Ocular Chlamydia trachomatis Infection before and after Mass Antibiotic Treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33109267" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : DjinniChip: evaluation of a novel molecular rapid diagnostic device for the detection of Chlamydia trachomatis in trachoma-endemic areas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32970672" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : The use of serology for trachoma surveillance: Current status and priorities for future investigation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37277341" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Monitoring transmission intensity of trachoma with serology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30575720" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : The utility of serology for elimination surveillance of trachoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23133684" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : CT694 and pgp3 as serological tools for monitoring trachoma programs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29694816" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Azithromycin to Reduce Childhood Mortality in Sub-Saharan Africa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29694816" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Azithromycin to Reduce Childhood Mortality in Sub-Saharan Africa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8102427" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Randomised controlled trial of single-dose azithromycin in treatment of trachoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9114186" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : A comparison of oral azithromycin with topical oxytetracycline/polymyxin for the treatment of trachoma in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8637698" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Single-dose azithromycin in the treatment of trachoma. A randomized, controlled study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31554017" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Antibiotics for trachoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30292480" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Antimicrobial resistance following mass azithromycin distribution for trachoma: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10574809" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Alterations in the conjunctival bacterial flora following a single dose of azithromycin in a trachoma endemic area.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9114185" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : A prospective study of the impact of community-based azithromycin treatment of trachoma on carriage and resistance of Streptococcus pneumoniae.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23487375" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Mass distribution of azithromycin for trachoma control is associated with increased risk of azithromycin-resistant Streptococcus pneumoniae carriage in young children 6 months after treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12543738" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Community treatment with azithromycin for trachoma is not associated with antibiotic resistance in Streptococcus pneumoniae at 1 year.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26557143" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Antibiotic Resistance in Streptococcus pneumoniae after Azithromycin Distribution for Trachoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16214600" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Infection with Chlamydia trachomatis after mass treatment of a trachoma hyperendemic community in Tanzania: a longitudinal study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14507864" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Which members of a community need antibiotics to control trachoma? Conjunctival Chlamydia trachomatis infection load in Gambian villages.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17003397" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Impact of annual targeted treatment on infectious trachoma and susceptibility to reinfection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10466664" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Azithromycin in control of trachoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11477966" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Efficacy of oral azithromycin versus topical tetracycline in mass treatment of endemic trachoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15623758" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Mass treatment and the effect on the load of Chlamydia trachomatis infection in a trachoma-hyperendemic community.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15623758" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Mass treatment and the effect on the load of Chlamydia trachomatis infection in a trachoma-hyperendemic community.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15623758" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Mass treatment and the effect on the load of Chlamydia trachomatis infection in a trachoma-hyperendemic community.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15623758" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Mass treatment and the effect on the load of Chlamydia trachomatis infection in a trachoma-hyperendemic community.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19724043" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Effect of mass distribution of azithromycin for trachoma control on overall mortality in Ethiopian children: a randomized trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22192488" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Comparison of annual versus twice-yearly mass azithromycin treatment for hyperendemic trachoma in Ethiopia: a cluster-randomised trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18434662" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Two doses of azithromycin to eliminate trachoma in a Tanzanian community.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10229236" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Global elimination of trachoma: how frequently should we administer mass chemotherapy?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15304470" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Feasibility of eliminating ocular Chlamydia trachomatis with repeat mass antibiotic treatments.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18194094" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Complete elimination is a difficult goal for trachoma programs in severely affected communities.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18285589" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Comparison of annual and biannual mass antibiotic administration for elimination of infectious trachoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33534757" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Twelve-Year Longitudinal Trends in Trachoma Prevalence among Children Aged 1-9 Years in Amhara, Ethiopia, 2007-2019.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27956455" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : A Cluster-Randomized Trial to Assess the Efficacy of Targeting Trachoma Treatment to Children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31167050" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Longer-Term Assessment of Azithromycin for Reducing Childhood Mortality in Africa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26392160" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : The Effect of Mass Azithromycin Distribution on Childhood Mortality: Beliefs and Estimates of Efficacy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21427395" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Childhood mortality in a cohort treated with mass azithromycin for trachoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30699301" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Effect of Adding Azithromycin to Seasonal Malaria Chemoprevention.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31167060" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Macrolide Resistance in MORDOR I - A Cluster-Randomized Trial in Niger.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33176084" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Macrolide and Nonmacrolide Resistance with Mass Azithromycin Distribution.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30950493" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Morbidity in a Longitudinal Cohort of Children Residing in Villages Randomized to Biannual Treatment With Azithromycin Versus Placebo.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26774708" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Posterior lamellar versus bilamellar tarsal rotation surgery for trachomatous trichiasis in Ethiopia: a randomised controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26774709" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Optimising the management of trachomatous trichiasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31891136" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Posterior lamellar versus bilamellar tarsal rotation surgery for trachomatous trichiasis: Long-term outcomes from a randomised controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25768796" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Epilation for minor trachomatous trichiasis: four-year results of a randomised controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1580842" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : A controlled trial of surgery for trachomatous trichiasis of the upper lid.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22180731" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Surgery versus epilation for the treatment of minor trichiasis in Ethiopia: a randomised controlled noninferiority trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22180731" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Surgery versus epilation for the treatment of minor trichiasis in Ethiopia: a randomised controlled noninferiority trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17994436" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Azithromycin prevents recurrence of severe trichiasis following trichiasis surgery: STAR trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16687452" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Impact of oral azithromycin on recurrence of trachomatous trichiasis in Nepal over 1 year.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22159169" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Three-year outcomes of the surgery for trichiasis, antibiotics to prevent recurrence trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16170117" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : A randomised controlled trial of azithromycin following surgery for trachomatous trichiasis in the Gambia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16534049" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Single-dose azithromycin prevents trichiasis recurrence following surgery: randomized trial in Ethiopia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29653629" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Oral doxycycline for the prevention of postoperative trachomatous trichiasis in Ethiopia: a randomised, double-blind, placebo-controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8435423" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Results of community-based eyelid surgery for trichiasis due to trachoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11584844" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Long-term follow-up of lid surgery for trichiasis in the Gambia: surgical success and patient perceptions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11471085" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Recurrence of trichiasis: a long-term follow-up study in the Sultanate of Oman.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15317698" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : One year recurrence of trachomatous trichiasis in routinely operated Cuenod Nataf procedure cases in Vietnam.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15834088" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Long term outcome of trichiasis surgery in the Gambia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22569465" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Trachoma:  an update on prevention, diagnosis, and treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22569465" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Trachoma:  an update on prevention, diagnosis, and treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22569465" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Trachoma:  an update on prevention, diagnosis, and treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22569465" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Trachoma:  an update on prevention, diagnosis, and treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22569465" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Trachoma:  an update on prevention, diagnosis, and treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2597076" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Hygiene factors and increased risk of trachoma in central Tanzania.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10933266" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Risk factors for trachoma: 6-year follow-up of children aged 1 and 2 years.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25697765" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Face washing promotion for preventing active trachoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33203456" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : Facial cleanliness indicators by time of day: results of a cross-sectional trachoma prevalence survey in Senegal.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31727155" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : Associations between Water, Sanitation and Hygiene (WASH) and trachoma clustering at aggregate spatial scales, Amhara, Ethiopia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7823670" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : Impact of face-washing on trachoma in Kongwa, Tanzania.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : Water, sanitation, and hygiene for control of trachoma in Ethiopia (WUHA): a two-arm, parallel-group, cluster-randomised trial</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : Water, sanitation, and hygiene for control of trachoma in Ethiopia (WUHA): a two-arm, parallel-group, cluster-randomised trial</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22336798" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : Environmental sanitary interventions for preventing active trachoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22336798" id="rid107" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>108 : Environmental sanitary interventions for preventing active trachoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22336798" id="rid108" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>109 : Environmental sanitary interventions for preventing active trachoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24586120" id="rid109" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>110 : Effect of water, sanitation, and hygiene on the prevention of trachoma: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2706728" id="rid110" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>111 : Water availability and trachoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32043457" id="rid111" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>112 : Comparison of Face Washing and Face Wiping Methods for Trachoma Control: A Pilot Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16905024" id="rid112" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>113 : Intensive insecticide spraying for fly control after mass antibiotic treatment for trachoma in a hyperendemic setting: a randomised trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15064026" id="rid113" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>114 : Role of flies and provision of latrines in trachoma control: cluster-randomised controlled trial.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
